Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 6 of 6 entries
Sorted by: Best Match Show Resources per page
Human eosinophil isolation and the measurement of apoptosis.

Methods in molecular medicine

Kankaanranta H, de Souza PM, Giembycz MA, Lindsay MA.
PMID: 21312124
Methods Mol Med. 2000;44:99-110. doi: 10.1385/1-59259-072-1:99.

Eosinophils have been implicated in allergic diseases, such as bronchial asthma, which is characterized by elevated eosinophil numbers in the bronchoalveolar lavage fluid and peripheral blood. Their accumulation and activation within the airway mucosa is thought to cause tissue...

Cite
Kankaanranta H, de Souza PM, Giembycz MA, et al. Human eosinophil isolation and the measurement of apoptosis. Methods Mol Med. 2000;44:99-110doi: 10.1385/1-59259-072-1:99.
Kankaanranta, H., de Souza, P. M., Giembycz, M. A., & Lindsay, M. A. (2000). Human eosinophil isolation and the measurement of apoptosis. Methods in molecular medicine, 4499-110. https://doi.org/10.1385/1-59259-072-1:99
Kankaanranta, H, et al. "Human eosinophil isolation and the measurement of apoptosis." Methods in molecular medicine vol. 44 (2000): 99-110. doi: https://doi.org/10.1385/1-59259-072-1:99
Kankaanranta H, de Souza PM, Giembycz MA, Lindsay MA. Human eosinophil isolation and the measurement of apoptosis. Methods Mol Med. 2000;44:99-110. doi: 10.1385/1-59259-072-1:99. PMID: 21312124.
Copy Download .nbib Format: NLM
Dual Transmembrane Signalling Mechanisms in Eosinophils: Evidence for Two Functionally Distinct Receptors for Platelet-Activating Factor.

International archives of allergy and immunology

Kroegel C, Warner JA, Giembycz MA, Matthys H, Lichtenstein LM, Barnes PJ.
PMID: 34167200
Int Arch Allergy Immunol. 1992;99(2):226-229. doi: 10.1159/000236253. Epub 2009 Sep 02.

The effect of PAF on eosinophil activation was investigated. TxB2 release required a lower concentration of PAF (ED50 = 17.2 nM) whereas for superoxide anion (O2) production doses in excess of 1 μM (ED50 = 31.7 μM) were needed....

Cite
Kroegel C, Warner JA, Giembycz MA, et al. Dual Transmembrane Signalling Mechanisms in Eosinophils: Evidence for Two Functionally Distinct Receptors for Platelet-Activating Factor. Int Arch Allergy Immunol. 2009;99(2):226-229doi: 10.1159/000236253.
Kroegel, C., Warner, J. A., Giembycz, M. A., Matthys, H., Lichtenstein, L. M., & Barnes, P. J. (1992). Dual Transmembrane Signalling Mechanisms in Eosinophils: Evidence for Two Functionally Distinct Receptors for Platelet-Activating Factor. International archives of allergy and immunology, 99(2), 226-229. https://doi.org/10.1159/000236253
Kroegel, Claus, et al. "Dual Transmembrane Signalling Mechanisms in Eosinophils: Evidence for Two Functionally Distinct Receptors for Platelet-Activating Factor." International archives of allergy and immunology vol. 99,2 (1992): 226-229. doi: https://doi.org/10.1159/000236253
Kroegel C, Warner JA, Giembycz MA, Matthys H, Lichtenstein LM, Barnes PJ. Dual Transmembrane Signalling Mechanisms in Eosinophils: Evidence for Two Functionally Distinct Receptors for Platelet-Activating Factor. Int Arch Allergy Immunol. 1992;99(2):226-229. doi: 10.1159/000236253. Epub 2009 Sep 02. PMID: 34167200.
Copy Download .nbib Format: NLM
A bronchoprotective role for .

Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology

George T, Chakraborty M, Giembycz MA, Newton R.
PMID: 30305828
Allergy Asthma Clin Immunol. 2018 Oct 01;14:40. doi: 10.1186/s13223-018-0266-5. eCollection 2018.

BACKGROUND: Asthma exacerbations are associated with the recruitment of neutrophils to the lungs. These cells release proteases and mediators, many of which act at G protein-coupled receptors (GPCRs) that couple via Gq to promote bronchoconstriction and inflammation. Common asthma...

Cite
George T, Chakraborty M, Giembycz MA, et al. A bronchoprotective role for . Allergy Asthma Clin Immunol. 2018;14:40doi: 10.1186/s13223-018-0266-5.
George, T., Chakraborty, M., Giembycz, M. A., & Newton, R. (2018). A bronchoprotective role for . Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology, 1440. https://doi.org/10.1186/s13223-018-0266-5
George, Tresa, et al. "A bronchoprotective role for ." Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology vol. 14 (2018): 40. doi: https://doi.org/10.1186/s13223-018-0266-5
George T, Chakraborty M, Giembycz MA, Newton R. A bronchoprotective role for . Allergy Asthma Clin Immunol. 2018 Oct 01;14:40. doi: 10.1186/s13223-018-0266-5. eCollection 2018. PMID: 30305828; PMCID: PMC6166284.
Copy Download .nbib Format: NLM
MAP Kinase Expression in Eosinophils.

Methods in molecular medicine

de Souza PM, Kankaanranta H, Giembycz MA, Lindsay MA.
PMID: 21312123
Methods Mol Med. 2000;44:91-8. doi: 10.1385/1-59259-072-1:91.

The mitogen-activated protein kinases (MAPK) are an expanding family of proline-directed serine/threonine kinases that are activated, following their dual phosphorylation at conserved threonine and tyrosine residues, by a family of MAPK kinases (MEK). Presently, the MAPK family can be...

Cite
de Souza PM, Kankaanranta H, Giembycz MA, et al. MAP Kinase Expression in Eosinophils. Methods Mol Med. 2000;44:91-8doi: 10.1385/1-59259-072-1:91.
de Souza, P. M., Kankaanranta, H., Giembycz, M. A., & Lindsay, M. A. (2000). MAP Kinase Expression in Eosinophils. Methods in molecular medicine, 4491-8. https://doi.org/10.1385/1-59259-072-1:91
de Souza, P M, et al. "MAP Kinase Expression in Eosinophils." Methods in molecular medicine vol. 44 (2000): 91-8. doi: https://doi.org/10.1385/1-59259-072-1:91
de Souza PM, Kankaanranta H, Giembycz MA, Lindsay MA. MAP Kinase Expression in Eosinophils. Methods Mol Med. 2000;44:91-8. doi: 10.1385/1-59259-072-1:91. PMID: 21312123.
Copy Download .nbib Format: NLM
Potential mechanisms to explain how LABAs and PDE4 inhibitors enhance the clinical efficacy of glucocorticoids in inflammatory lung diseases.

F1000prime reports

Giembycz MA, Newton R.
PMID: 25750734
F1000Prime Rep. 2015 Feb 03;7:16. doi: 10.12703/P7-16. eCollection 2015.

Inhaled glucocorticoids acting via the glucocorticoid receptor are a mainstay treatment option for individuals with asthma. There is a consensus that the remedial actions of inhaled glucocorticoids are due to their ability to suppress inflammation by modulating gene expression....

Cite
Giembycz MA, Newton R. Potential mechanisms to explain how LABAs and PDE4 inhibitors enhance the clinical efficacy of glucocorticoids in inflammatory lung diseases. F1000Prime Rep. 2015;7:16doi: 10.12703/P7-16.
Giembycz, M. A., & Newton, R. (2015). Potential mechanisms to explain how LABAs and PDE4 inhibitors enhance the clinical efficacy of glucocorticoids in inflammatory lung diseases. F1000prime reports, 716. https://doi.org/10.12703/P7-16
Giembycz, Mark A, and Newton, Robert. "Potential mechanisms to explain how LABAs and PDE4 inhibitors enhance the clinical efficacy of glucocorticoids in inflammatory lung diseases." F1000prime reports vol. 7 (2015): 16. doi: https://doi.org/10.12703/P7-16
Giembycz MA, Newton R. Potential mechanisms to explain how LABAs and PDE4 inhibitors enhance the clinical efficacy of glucocorticoids in inflammatory lung diseases. F1000Prime Rep. 2015 Feb 03;7:16. doi: 10.12703/P7-16. eCollection 2015. PMID: 25750734; PMCID: PMC4335793.
Copy Download .nbib Format: NLM
Editorial: Phosphodiesterases as Drug Targets in Airway and Inflammatory Diseases.

Frontiers in pharmacology

Mokry J, Giembycz M, Mokra D.
PMID: 33912063
Front Pharmacol. 2021 Apr 12;12:657596. doi: 10.3389/fphar.2021.657596. eCollection 2021.

No abstract available.

Cite
Mokry J, Giembycz M, Mokra D. Editorial: Phosphodiesterases as Drug Targets in Airway and Inflammatory Diseases. Front Pharmacol. 2021;12:657596doi: 10.3389/fphar.2021.657596.
Mokry, J., Giembycz, M., & Mokra, D. (2021). Editorial: Phosphodiesterases as Drug Targets in Airway and Inflammatory Diseases. Frontiers in pharmacology, 12657596. https://doi.org/10.3389/fphar.2021.657596
Mokry, Juraj, et al. "Editorial: Phosphodiesterases as Drug Targets in Airway and Inflammatory Diseases." Frontiers in pharmacology vol. 12 (2021): 657596. doi: https://doi.org/10.3389/fphar.2021.657596
Mokry J, Giembycz M, Mokra D. Editorial: Phosphodiesterases as Drug Targets in Airway and Inflammatory Diseases. Front Pharmacol. 2021 Apr 12;12:657596. doi: 10.3389/fphar.2021.657596. eCollection 2021. PMID: 33912063; PMCID: PMC8072865.
Copy Download .nbib Format: NLM
Showing 1 to 6 of 6 entries